Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1993 1
2000 1
2002 1
2003 1
2004 1
2008 2
2009 1
2010 3
2011 2
2012 2
2014 1
2015 2
2016 3
2017 3
2018 8
2019 7
2020 6
2021 13
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Results by year
Filters applied: . Clear all
Page 1
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT; NEO1 Investigator Group. Pena LDM, et al. Among authors: shafi r. Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17. Neuromuscul Disord. 2019. PMID: 30770310 Free article. Clinical Trial.
Dementia Care at End of Life: Current Approaches.
Bartley MM, Suarez L, Shafi RMA, Baruth JM, Benarroch AJM, Lapid MI. Bartley MM, et al. Among authors: shafi rma. Curr Psychiatry Rep. 2018 Jun 23;20(7):50. doi: 10.1007/s11920-018-0915-x. Curr Psychiatry Rep. 2018. PMID: 29936639 Review.
58 results